Locally Advanced Breast Cancer
Conditions
Keywords
Locally Advanced Breast Cancer, prognosis
Brief summary
The goal of this clinical trial is to compare the therapeutic effects of chemotherapy followed by surgery and surgery followed by chemotherapy in patients with locally advanced breast cancer（LABC). Patients with LABC will be randomly divided into two groups, each receiving chemotherapy followed by surgery or surgery followed by chemotherapy. The main comparison was between the disease-free survival (DFS) of two groups of patients, with the secondary study endpoint being overall survival (OS); Five year survival; Local recurrence or distant metastasis rate.
Detailed description
Local advanced breast cancer was enrolled in the Department of Breast Surgery of Peking Union Medical College Hospital and Beijing Cooperation Hospital according to the criteria for patient inclusion. It is estimated that 50 patients will be enrolled. Randomly divide patients into two groups. The plan for Group A (experimental group, 25 cases) is surgery+systematic treatment; The plan for Group B (control group, 25 cases) is neoadjuvant therapy+surgery+systematic treatment. Based on the previously obtained patient personal information, treatment related information, tumor tissue/blood sample test results, statistical analysis was conducted to explore the impact of different treatment strategies for locally advanced breast cancer on the survival and prognosis of patients.
Interventions
PROCEDUREModified radical mastectomy for breast cancer
Modified radical mastectomy for breast cancer
PROCEDUREneoadjuvant therapy
neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）
PROCEDURESystematic treatment
chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The plan for Group A (experimental group) is surgery+systematic treatment; The plan for Group B (control group) is neoadjuvant therapy+surgery+systematic treatment.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. 18-70 year old female 2. Patients with locally advanced breast cancer (stage IIIb - IIIc) first diagnosed; 3. Clinical diagnosis of breast cancer, or puncture pathology suggests breast cancer; 4. After evaluation by experienced clinical physicians, the patient's tumor has the possibility of surgical resection. Specific evaluation indicators include ultrasound assessment of the tumor not surrounding the axillary vein; 5. Accept treatment plans including surgery, radiotherapy, and chemotherapy; 6. Volunteer to participate in clinical research and sign an informed consent form; 7. Willing to undergo follow-up and complete quality of life (EQ-5D series scale and FACT-B scale) and postoperative psychological status (Anxiety/Depression Self Rating Scale) assessments;
Exclusion criteria
1. Patients under 18 years old or over 70 years old; 2. Those who have received breast cancer related surgery, radiotherapy or chemotherapy; 3. Those who are not expected to receive surgery, radiotherapy or chemotherapy related to breast cancer 4. History of other malignant tumors; 5. Pregnant or lactating women; 6. Accompanying active infection and fever; 7. Other serious diseases that may significantly affect clinical trial compliance, such as severe cardiopulmonary dysfunction, liver and kidney dysfunction, poorly controlled diabetes and mental illness.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DFS | 1 year；3 years；5 years | Disease-free survival of patients with locally advanced breast cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local recurrence or distant metastasis rate | 1 year；3 years；5 years | Local recurrence or distant metastasis rate of patients with locally advanced breast cancer |
| OS | 1 year；3 years；5 years | Overall survival of patients with locally advanced breast cancer |
| Five year survival rate | 1 year；3 years；5 years | Five year survival rate of patients with locally advanced breast cancer |
Countries
China
Contacts
Primary ContactYing Xu
Outcome results
None listed